– Significant commercial strategy and product launch experience –– ATTACK Phase 3 top-line data readout remains on-track for 2H 2021 – WALTHAM, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the appointment of Anna Diaz Triola as Chief Commercial Officer, effective July 19th 2021. Ms. Triola will be responsible for global commercial strategy, including U.S. sales and marketing operations. "With the ATTACK Phase 3 registration clinical trial nearing completion, we are now engaged in preparing for commercialization

Wedbush downgraded Entasis Therapeutics Hldg from Outperform to Neutral and set a new price target of $1.80 from $9.00 previously

HC Wainwright & Co. downgraded Entasis Therapeutics Hldg from Buy to Neutral and set a new price target of $1.80 from $6.00 previously

BMO Capital reiterated coverage of Entasis Therapeutics Hldg with a rating of Outperform and set a new price target of $7.00 from $5.00 previously

HC Wainwright & Co. reiterated coverage of Entasis Therapeutics Hldg with a rating of Buy and set a new price target of $6.00 from $5.00 previously

WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (NASDAQ:INVA), today announced that six abstracts highlighting sulbactam-durlobactam (SUL-DUR) have been selected for presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C. Details of the presentations are as follows: Oral Presentations: Title: Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: sulbactam-durlobactam

Innoviva, Inc. (NASDAQ:INVA) ("Innoviva") today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis") at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022. The depositary for the tender offer has advised that, as of the expiration of the tender offer, a total of 11,671,662 shares of Entasis' common stock were validly tendered and not withdrawn in the tender offer. Such shares of Entasis' common stock, upon excluding those tendered by Manoussos Perros (the "

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society for Microbiology (ASM) annual Microbe conference, taking place June 9-13, 2022, in Washington, DC. Entasis is presenting data on sulbactam-durlobactam (SUL-DUR), an investigational drug in development for the treatment of infections caused by Acinetobacter baumannii including carbapenem-resistant and multidrug-resistant (MDR) strains, and ETX0462 a novel, first-in-class, diazabicyclooctane with broad spectrum

Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cashPrice per share in cash represents a 50% premium to Entasis' closing price of $1.47 per share on January 31, 2022, the last date before Innoviva's original bid became publicTransaction advances Innoviva's strategy to acquire differentiated, promising healthcare assets BURLINGAME, Calif. and WALTHAM, Mass., May 23, 2022 (GLOBE NEWSWIRE) -- Innoviva, Inc. (NASDAQ:INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis"), an advanced late-stage cl

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company presented data highlights from its pivotal Phase 3 ATTACK trial at the American Thoracic Society (ATS) annual conference, held this week from May 16-18, 2022, in San Francisco, California. The poster presentation―P628 Sulbactam-Durlobactam (SUL-DUR) Treatment Is Associated with Lower Mortality from Index Acinetobacter Infections in the Attack Phase 3 Registrational Trial―presented key data from the landmark ATTACK trial. Sulbactam-durlobac

Royalties increased by 5% to $93.5 million in the first quarter of 2022, compared to the same quarter in 2021. Issued $261.0 million convertible senior notes due 2028 and repurchased a portion of the convertible subordinated notes due 2023. Invested $45.0 million into Armata Pharmaceuticals Inc. (NYSE:ARMP) ("Armata"), an anti-infectives leader. Made a non-binding offer to acquire and provided $15.0 million convertible debt financing to Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis"), an anti-infectives leader. Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") today reported financial results for the first quarter ended March 31, 2022. Gross royalty revenue

Highlights of landmark Phase 3 ATTACK trial for sulbactam-durlobactam (SUL-DUR) presented at ECCMID 2022 annual conferenceSUL-DUR NDA submission on track for mid-2022Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023 WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced its first quarter 2022 financial results and provided a business update. "During our first quarter we continued to advance our pipeline and lay the foundations of our development into a fully

WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that top-line data from the company's pivotal Phase 3 ATTACK trial was presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual conference, held April 23-26, 2022 in Lisbon, Portugal. In Entasis's first oral presentation, Dr. Alita Miller, PhD, Vice President, Microbiology discussed the Characterization of Acinetobacter baumannii-calcoaceticus complex (ABC) pathogens isolated at baseline from patients e

WALTHAM, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company will deliver multiple data presentations on sulbactam-durlobactam (SUL-DUR) at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual conference, to be held April 23-26, 2022 in Lisbon, Portugal.   Among the seven presentations on SUL-DUR, Entasis Therapeutics will deliver two oral presentations and three posters on the topline results from its ATTACK trial—a global Phase 3 registrational tr

Phase 3 ATTACK registrational trial for sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints, NDA submission planned for mid-2022Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023Entasis' pathogen-directed platform and latest candidate ETX0462 highlighted by seminal publication in the prestigious scientific journal NatureReceipt of acquisition proposal from existing majority shareholder Innoviva, Inc. WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, toda

15-12G - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)

EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)

EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)

EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)

EFFECT - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)

S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)

S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)

S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)

S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)

S-8 POS - Entasis Therapeutics Holdings Inc. (0001724344) (Filer)

US producer prices likely to rise 0.8% on the month in June to match the previous month’s growth. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3 SeaChange International The Trade: SeaChange International, Inc. (NASDAQ:SEAC) 10% owner Karen Singer acquired a total of 424,942 shares at an avera

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society for Microbiology (ASM) annual Microbe conference, taking place June 9-13, 2022, in Washington, DC. Entasis is presenting data on sulbactam-durlobactam (SUL-DUR), an investigational drug in development for the treatment of infections caused by Acinetobacter baumannii including carbapenem-resistant and multidrug-resistant (MDR) strains, and ETX0462 a novel, first-in-class, diazabicyclooctane with broad spectrum antimicrobial activity against MDR Gram-negative bac

Gainers Catalyst Biosciences, Inc. (NASDAQ:CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million. GeoVax Labs, Inc. (NASDAQ:GOVX) surged 66.9% to settle at $2.32 after Maxim Group reiterated a Buy rating on the stock and announced a $6 price target. Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) rose 58% to settle at $3.16. View, Inc. (NASDAQ:VIEW) gained 43.4% to close at $0.9765. Predictive Oncology Inc. (NASDAQ:POAI) gained 40.7% to close at $0.38. Predictive Oncology recently reported closing of $7.2 million registered direct offerings. Standard BioTools Inc. (NASDAQ:LAB) surged 33.3% to close at $2.60. Evolve Trans

Innoviva Inc (NASDAQ:INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) at $2.20 per share in cash.  Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis' equity at $113 million on a fully diluted basis. "This acquisition will build upon our overall strategy to acquire differentiated, high-potential assets in attractive, yet often overlooked, disease areas where our capital and capabilities can make a difference," said Pavel Raifeld, Chief Executive Officer of Innoviva.  "We look forward to working with the Entasis team to advance sulbactam-durlobactam (SUL-DUR) and its broader

Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading period, Coupang closed at $11.99. According to Guggenheim, the prior rating for NextGen Healthcare Inc (NASDAQ:NXGN) was changed from Neutral to Buy. In the third quarter, NextGen Healthcare showed an EPS of $0.24, compared to $0.26 from the year-ago quarter. The stock has a 52-week-high of $21.87 and a 52-week-low of $13.64. At the end of the last trading period, NextGen Healthcare closed at $19.52. According to CLSA, the prior rating for Melco Resorts and Entertainment Ltd (NASDAQ:MLCO

Keybanc cut HubSpot, Inc. (NYSE:HUBS) price target from $535 to $461. HubSpot shares fell 0.4% to $340.00 in pre-market trading. Cantor Fitzgerald cut the price target for Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) from $5 to $2. Entasis Therapeutics shares closed at $1.89 on Thursday. Piper Sandler raised the price target on Boot Barn Holdings, Inc. (NYSE:BOOT) from $109 to $121. Boot Barn shares rose 1.6% to $97.27 in pre-market trading. DA Davidson lowered the price target for Nature's Sunshine Products, Inc. (NASDAQ:NATR) from $24.5 to $18. Nature's Sunshine Products shares fell 0.9% to $15.56 in pre-market trading. Telsey Advisory Group boosted the price target on G

Cantor Fitzgerald analyst Louise Chen downgrades Entasis Therapeutics Hldg (NASDAQ:ETTX) from Overweight to Neutral and lowers the price target from $5 to $2.